Production (Stage)
Inhibitor Therapeutics, Inc.
INTI
$0.054
$0.0048.00%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.49% | 20.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -54.55% | 82.51% | |||
| Operating Income | 54.55% | -82.51% | |||
| Income Before Tax | 55.49% | -94.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 55.49% | -94.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.49% | -94.50% | |||
| EBIT | 54.55% | -82.51% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 55.42% | -97.62% | |||
| Normalized Basic EPS | 55.77% | -92.59% | |||
| EPS Diluted | 55.42% | -97.62% | |||
| Normalized Diluted EPS | 55.77% | -92.59% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||